Ajax Therapeutics
Targeting cancer through precise selectivity
New York, United States · Founded 2019 · $143.0M raised
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- ajaxtherapeutics.com
- Total Funding
- $143.0M
- Last Round
- $8.0M Series AMay 2024
- Rounds
- 3
About
Ajax Therapeutics is a clinical-stage biotechnology company applying computational chemistry and structural biology to develop next-generation JAK2 inhibitors for myeloproliferative neoplasms (MPNs). Their lead candidate, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical trials for myelofibrosis. The company has raised $143M from investors including Goldman Sachs, Eli Lilly, and RA Capital Management.
Summary
Ajax Therapeutics is a Biotech company based in New York, United States, founded in 2019. It has raised $143.0M in total across 3 rounds, most recently a $8.0M Series A round in May 2024. Investors include EcoR1 Capital, OrbiMed and Goldman Sachs Alternatives.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.